Oligonucleotides

Home
Immunoassays
Modalities
Oligonucleotides

Oligonucleotide analysis with the Gyrolab immunoassay platform

Oligonucleotide-based therapies are a growing part of modern drug development, including antisense oligonucleotides (ASO), siRNA, and mRNA. These molecules require sensitive and reliable analytical methods to quantify distribution, exposure, and stability across biological matrices.

Gyrolab supports oligonucleotide workflows with automated hybridization assays designed for small sample volumes, high sensitivity, and consistent performance. This makes it well suited for pharmacokinetic studies and tissue distribution analysis across development stages.

Common oligonucleotide modalities include:

Antisense oligonucleotides (ASO) - Single-stranded molecules designed to bind RNA and modulate gene expression.
Small Interfering RNAs (siRNA) - Double-stranded RNA molecules that degrade target mRNA and reduce protein expression.
Messenger RNA (mRNA) - Synthetic RNA used to instruct cells to produce therapeutic proteins.
Antibody-oligonucleotide conjugates (AOC) - Combine targeted delivery from antibodies with the functional effect of oligonucleotides.

Hybridization assays for oligo detection

Hybridization assays differ from traditional immunoassays by using complementary oligonucleotide sequences instead of antibodies for capture and detection. This enables selective and sensitive detection of oligonucleotide drugs in complex biological samples.

Dual hybridization assay (DHA)
Uses one capture and one detection oligonucleotide. Signal is generated only when the target analyte binds both probes, improving specificity.

Nuclease-dependent cutting assay (NCA)
Uses a full-length probe that is cleaved unless bound to the target. This improves selectivity for the intact parent oligonucleotide and reduces background signal.